Reaction

Product Preparation Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,752 reports · 93 co-occurring drugs

As of the last recalculation, Product Preparation Issue appears in 5,752 FAERS reports alongside 93 co-occurring drug terms. The strongest observed disproportionality signal is BOTULINUM TOXIN TYPE A (PRR 40.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Botulinum Toxin Type A	135	40.3	40.7
Onabotulinumtoxina	731	39.1	39.5
Clobazam	150	22.8	22.9
Cabotegravir	30	13.5	13.6
Somatropin	219	11.2	11.2
Remdesivir	39	10.7	10.7
Cannabidiol	68	10.6	10.7
Iron Sucrose	26	9.9	9.9
Agalsidase Beta	20	7.9	7.9
Ravulizumab	27	7.3	7.3
Alirocumab	45	6.5	6.5
Bupivacaine	15	5.8	5.8
Instalax Polyethylene Glycol 3350	19	5.6	5.6
Polyethylene Glycol 400	19	5.4	5.4
Teduglutide	20	5.4	5.4
Naltrexone	45	5.3	5.3
Belimumab	46	5.3	5.3
Sodium Chloride	108	5.0	5.0
Sodium Chloride Tablet	100	5.0	5.0
Sodium Chloride Tablets	100	5.0	5.0
Guanfacine	10	4.6	4.6
Dutasteride	10	4.5	4.5
Alteplase	18	4.3	4.4
Ipilimumab	51	4.3	4.3
Ado-Trastuzumab Emtansine	10	4.3	4.3
Phenobarbital	17	4.3	4.3
Vigabatrin	17	4.2	4.2
Budesonide, Glycopyrrolate, And Formoterol Fumarate	11	3.8	3.8
Valproic Acid	33	3.8	3.8
Calcium, Magnesium, Potassium, And Sodium Oxybates	9	3.8	3.8
Midazolam	26	3.7	3.7
Abatacept	133	3.5	3.5
Leuprolide Acetate	75	3.5	3.5
Human Immunoglobulin G	20	3.5	3.5
Cefuroxime	11	3.5	3.5
Cenobamate	8	3.5	3.5
Zonisamide	14	3.4	3.4
Sodium Oxybate	62	3.4	3.4
Buspirone Hydrochloride	10	3.3	3.3
Mepolizumab	44	3.2	3.2
Melatonin	48	3.2	3.2
Patiromer	12	3.1	3.1
Romiplostim	13	3.1	3.1
Tretinoin	7	3.1	3.1
Midazolam Hydrochloride	22	3.0	3.0
Divalproex Sodium	37	2.9	2.9
Adrenalinum	33	2.9	2.9
Testosterone Cypionate	7	2.8	2.8
Brivaracetam	7	2.8	2.8
Dupilumab	336	2.6	2.6
Fam-Trastuzumab Deruxtecan-Nxki	7	2.5	2.5
Hydroxyzine Hydrochloride	9	2.5	2.5
Hydroxyzine Hydrochloride Oral	9	2.5	2.5
Polyethylene Glycol 3350	65	2.5	2.5
Epinephrine	43	2.4	2.4
Cetirizine Hcl	6	2.4	2.4
Triamcinolone Acetonide Ointment Usp, 0.05%	15	2.3	2.3
Asfotase Alfa	6	2.2	2.2
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	21	2.2	2.2
Panitumumab	9	2.1	2.1
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	23	2.0	2.0
Dolutegravir Sodium	5	2.0	2.0
Epoprostenol	7	1.9	1.9
Levetiracetam	71	1.9	1.9
Polatuzumab Vedotin	5	1.9	1.9
Carfilzomib	14	1.8	1.8
Eculizumab	26	1.7	1.7
Blinatumomab	5	1.7	1.7
Nemolizumab-Ilto	6	1.7	1.7
Eptinezumab-Jjmr	4	1.6	1.6
Droxidopa	9	1.5	1.5
Nivolumab	40	1.5	1.5
Riociguat	13	1.4	1.4
Vedolizumab	34	1.4	1.4
Rimegepant Sulfate	5	1.4	1.4
Brentuximab Vedotin	4	1.4	1.4
Ocrelizumab	23	1.3	1.3
Obinutuzumab	6	1.3	1.3
Daratumumab	14	1.3	1.3
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	6	1.2	1.2
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	13	1.1	1.1
Treprostinil	39	1.1	1.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	3	1.1	1.1
Emtricitabine And Tenofovir Alafenamide	3	1.0	1.0
Aflibercept	8	0.9	0.9
Emicizumab	3	0.9	0.9
Voxelotor	5	0.8	0.8
Evolocumab	33	0.7	0.7
Bimekizumab	4	0.7	0.7
Minoxidil Foam 5% (Womens)	6	0.7	0.7
Nirmatrelvir And Ritonavir	8	0.5	0.5
Minoxidil	6	0.5	0.5
Salicylic Acid	3	0.2	0.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.